62321-91-9

Usage

Uses

Used in Scientific Research:
4-(Dimethylamino)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile is used as a chemical intermediate for the synthesis of various complex compounds in scientific research. Its unique structure and properties make it a valuable component in the development of new chemical entities.
Used in Chemical Industries:
In the chemical industry, 4-(Dimethylamino)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile is utilized as a precursor in the production of other compounds. Its role as a building block in chemical synthesis is essential for creating a wide range of products, from pharmaceuticals to specialty chemicals.
Used in Pharmaceutical Development:
4-(Dimethylamino)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile is employed as a key intermediate in the development of pharmaceuticals. Its presence in the synthesis process can contribute to the creation of new drugs with potential therapeutic applications.
Used in Specialty Chemical Production:
4-(DIMETHYLAMINO)-2-OXO-1,2-DIHYDRO-3-PYRIDINECARBONITRILE is also used in the production of specialty chemicals, where its unique properties can be leveraged to create products with specific characteristics, such as improved performance or novel functionalities.

InChI:InChI=1/C8H9N3O/c1-11(2)7-3-4-10-8(12)6(7)5-9/h3-4H,1-2H3,(H,10,12)

Upstream product

• 120650-90-0 α-cyano-β-dimethylaminocrotonamide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 62321-92-0 α-cyano-β-dimethylaminocrotonamide 

Downstream Products

• 147992-80-1 2-chloro-4-(dimethylamino)nicotinonitrile 
• 204765-71-9 3-amino-4-dimethylamino-2-phenylaminocarbonylmethylthiopyridine 
• 98694-73-6 2-amino-4-dimethylamino-3-cyanopyridine 

Relevant academic research and scientific papers

FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, part

Fused tricyclic mGIuR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGlu

mGluR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1—R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

Bifunctional catalysis of ester aminolysis - A computational and experimental study

Various pathways for the reaction of methylamine with methyl acetate catalyzed by 2(1H)-pyridone have been investigated at the Becke3LYP/6-31G**//HF/6-31G** level of theory. The most favorable pathway consists of a one-step reaction, in which all bond-forming and -breaking processes occur in concert. These modeling studies also show the pyridone to function as an acid, which led to the investigation of several substituted pyridones. 4-Cyano-, 3-cyano-6-methyl-, and 3-cyano-2(1H)-pyridone have indeed been shown to provide better catalysis in the ester aminolysis reaction by ab initio modeling at the Becke3LYP/6-31G**//HF/3-21G level. In order to verify the theoretical results, the catalytic activities of various substituted 2-pyridones in the reaction of n-butylamine with p-nitrophenyl acetate in chlorobenzene solution have been determined. The observed catalytic rate constants are indeed in agreement with the theoretical predictions. Other catalyst characteristics such as solubility and state of aggregation are, however, also of paramount importance in this reaction. VCH Verlagsgesellschaft mbH, 1996.